Achievement of the target number of subjects in the domestic Phase III clinical trial of the achondroplasia treatment umedaptanib pegol (WAKABA study)
RIBOMIC Inc. (filing company)
Participating medical institutions nationwide, umedaptanib pegol (RBM-007), WAKABA study, pediatric patients with achondroplasia (2–14 years old)
Because subject enrollment was conducted at participating medical institutions nationwide
Amount: Not disclosed. The impact on full-year results for the fiscal year ending March 2027 is minor
Full year ending March 2027 (the impact on results from this matter is minor)
The impact of this matter on full-year results for the fiscal year ending March 2027 is minor
Subjects who provided consent during the consent period are scheduled to be enrolled by the end of November 2026, and the final number of enrolled subjects may reach a maximum of 25. The company will continue to conduct the WAKABA study and advance development toward obtaining early approval for umedaptanib pegol.
| Item | Details |
|---|---|
| Event name | Achievement of the target number of subjects in the domestic Phase III clinical trial of the achondroplasia treatment umedaptanib pegol (WAKABA study) |
| Date of occurrence | 17 November 2026 (18 subjects enrolled as of this date) |
| Subject Entity | RIBOMIC Inc. (filing company) |
| Target Locations / Products | Participating medical institutions nationwide, umedaptanib pegol (RBM-007), WAKABA study, pediatric patients with achondroplasia (2–14 years old) |
| Cause | Because subject enrollment was conducted at participating medical institutions nationwide |
| Amount of Impact on Business Performance | Amount: Not disclosed. The impact on full-year results for the fiscal year ending March 2027 is minor |
| Accounting period in which recognized | Full year ending March 2027 (the impact on results from this matter is minor) |
| Impact on Earnings Forecast | The impact of this matter on full-year results for the fiscal year ending March 2027 is minor |
| Outlook | Subjects who provided consent during the consent period are scheduled to be enrolled by the end of November 2026, and the final number of enrolled subjects may reach a maximum of 25. The company will continue to conduct the WAKABA study and advance development toward obtaining early approval for umedaptanib pegol. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company explains that, after enrolling the first subject in July 2026, it proceeded with subject enrollment at participating medical institutions nationwide and achieved the target number of subjects as planned. It expects the enrollment above the target to contribute to the accumulation of more comprehensive clinical data.